Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0SX7F
|
|||
| Former ID |
DNC013055
|
|||
| Drug Name |
AZALANSTAT
|
|||
| Synonyms |
Azalanstat; RS-21607; UNII-2NL79NI1WS; 143393-27-5; 2NL79NI1WS; CHEMBL70611; 1-(((2S,4S)-4-(((p-Aminophenyl)thio)methyl)-2-(p-chlorophenethyl)-1,3-dioxolan-2-yl)methyl)imidazole; 4-[[(2S,4S)-2-[2-(4-chlorophenyl)ethyl]-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methylsulfanyl]aniline; Azalanstat [INN]; RS-21607197; RS 21607; AC1Q3NQV; AC1L1U3F; SCHEMBL1230519; GTPL8799; 4-{2-[2-(4-Chloro-phenyl)-ethyl]-2-imidazol-1-ylmethyl-[1,3]dioxolan-4-ylmethylsulfanyl}-phenylamine; BDBM50044424; compound 1 [PMID: 8340925]; Benzenamine, 4
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Hyperlipidaemia [ICD-11: 5C80; ICD-10: E78.5] | Discontinued in Phase 2 | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C22H24ClN3O2S
|
|||
| Canonical SMILES |
C1C(OC(O1)(CCC2=CC=C(C=C2)Cl)CN3C=CN=C3)CSC4=CC=C(C=C4)N
|
|||
| InChI |
1S/C22H24ClN3O2S/c23-18-3-1-17(2-4-18)9-10-22(15-26-12-11-25-16-26)27-13-20(28-22)14-29-21-7-5-19(24)6-8-21/h1-8,11-12,16,20H,9-10,13-15,24H2/t20-,22-/m0/s1
|
|||
| InChIKey |
VYNIUBZKEWJOJP-UNMCSNQZSA-N
|
|||
| CAS Number |
CAS 143393-27-5
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Candida Cytochrome P450 51 (Candi ERG11) | Target Info | Modulator | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002302) | |||
| REF 2 | Azalanstat (RS-21607), a lanosterol 14 alpha-demethylase inhibitor with cholesterol-lowering activity. Biochem Pharmacol. 1995 Aug 8;50(4):529-44. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.